Mar 2021
Agreement to Jointly Develop & Commercialize Long-acting, Investigational Combinations of Lenacapavir & Islatravir for the Treatment of HIV-1 with Merck
Financial Advisor
View Details >
Jul 2020
$300 Million
Jul 2020
Sale of Spleen Tyrosine Kinase (SYK) Inhibitor Portfolio to Kronos Bio
Financial Advisor
View Details >May 2020
$2 Billion